Welcome to our dedicated page for Atrium Therapeutics SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atrium Therapeutics filings document the corporate transition that created the current RNA issuer and the related Avidity Biosciences merger, separation and listing records. The filing set includes 8-K material-event reports, shareholder voting disclosures, separation and merger agreement records, capital-structure information and a Form 25 covering removal of Avidity common stock from Nasdaq listing and registration.
Regulatory disclosures tied to the symbol also cover governance matters, operating and financial results, clinical or regulatory updates and security-structure information. As an independent biopharmaceutical company, Atrium's filings center on its RNA therapeutics platform, precision cardiology pipeline, collaboration economics, equity compensation and public-company reporting obligations.
Atrium Therapeutics Schedule 13G discloses passive holdings by RA Capital and affiliates. The filing reports that RA Capital Healthcare Fund, L.P. directly holds 864,102 shares of Common Stock, representing 5.6% of the class based on 15,514,996 shares outstanding as of February 26, 2026. The filing explains that RA Capital serves as investment adviser and that voting and dispositive power over the Fund's shares are delegated to RA Capital; the Reporting Persons disclaim group status and disclaim beneficial ownership except as required for Section 13(d) purposes.
Atrium Therapeutics, Inc. reported its first quarter as an independent public company focused on RNA therapeutics for cardiomyopathies. Collaboration revenue reached $19.6 million, up sharply from $1.6 million a year earlier, mainly from a $15.0 million milestone under the Bristol Myers Squibb collaboration.
Operating expenses rose to $36.9 million, driven by higher research and development spending of $16.7 million and general and administrative costs of $20.3 million, including significant stock-based compensation linked to the Spin-Off. Atrium recorded a net loss of $16.6 million, or $0.97 per share, versus a $7.4 million loss in the prior-year quarter.
Following its separation from Avidity Biosciences and Spin-Off in February 2026, Atrium was capitalized with about $270.0 million in cash and ended March 31, 2026 with cash and cash equivalents of $267.8 million and total assets of $292.4 million. Management believes this cash will fund operations for at least 12 months and through Phase 1 proof-of-concept for lead candidate ATR 1072 targeting PRKAG2 syndrome, while advancing ATR 1086 for PLN cardiomyopathy and earlier pipeline programs.
Atrium Therapeutics, Inc. reported first quarter 2026 results following its launch as a public precision cardiology company. For the three months ended March 31, 2026, collaboration revenue was $19,635 thousand, up from $1,573 thousand a year earlier.
Total operating expenses rose to $36,915 thousand from $9,025 thousand, driven by higher research and development and general and administrative spending. Atrium recorded a net loss of $16,633 thousand, versus $7,449 thousand in the prior-year period, equal to a basic and diluted net loss per share of $0.97 compared with $0.44.
On the balance sheet as of March 31, 2026, cash and cash equivalents were $267,849 thousand, total assets were $292,360 thousand, and total liabilities were $58,256 thousand, resulting in stockholders’ equity of $234,104 thousand.
BlackRock, Inc. files a Schedule 13G reporting beneficial ownership of 892,387 shares of Atrium Therapeutics, Inc. common stock, representing 5.2% of the class as reported. The filing lists sole voting power for 880,175 shares and sole dispositive power for 892,387 shares. The cover date shown is 03/31/2026 and the Schedule is signed on 04/27/2026. The filing states the holdings reflect securities held by certain Reporting Business Units of BlackRock and notes various persons may have rights to dividends or sale proceeds.
Atrium Therapeutics, Inc. granted equity awards to executive Stephanie Kenney on April 20, 2026. She received 30,000 shares of common stock as restricted stock units, bringing her direct common stock holdings to 35,460 shares after the award.
Kenney was also granted stock options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over multiple years starting March 20, 2027, subject to her continued service with the company.
Atrium Therapeutics’ Chief Medical Officer Steven George Hughes reported new equity compensation consisting of restricted stock units and stock options. He received 30,000 RSUs, each representing one future share of common stock, bringing his directly held common shares to 73,097 after the award.
The RSUs vest over four years, with 25% vesting on March 20, 2027 and the rest in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036.
These options vest with 25% becoming exercisable on March 20, 2027 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter, also subject to continued service.
Atrium Therapeutics, Inc. reported that its Chief Financial Officer, Brendan R. Winslow, received equity compensation consisting of restricted stock units and stock options. He was granted 30,000 shares of Common Stock as an award, bringing his direct holdings to 43,601 shares after the transaction.
He was also granted 60,000 stock options to buy Common Stock at an exercise price of $14.30 per share, expiring on April 20, 2036. According to the award terms, 25% of the RSUs vest on March 20, 2027, with the remainder vesting in three yearly installments. For the options, 25% of the underlying shares vest on March 20, 2027, with the remaining shares vesting in 36 substantially equal monthly installments. These are compensation-related grants, not open-market purchases.
Atrium Therapeutics, Inc. director and officer Kathleen P. Gallagher reported receiving equity awards as part of her compensation. She was granted 102,500 shares of common stock in the form of restricted stock units, with each unit representing one future share of common stock, subject to vesting.
Gallagher was also granted a stock option for 205,000 shares of common stock at an exercise price of $14.30 per share. Twenty-five percent of both the RSUs and the option vest on March 20, 2027, with the remaining portions vesting over subsequent years, contingent on her continued service. After these grants, she directly owns 131,361 shares of common stock and holds the full 205,000-share stock option.
Atrium Therapeutics, Inc. reported that Chief Strategy Officer Rocio Martin Hoyos received equity-based compensation. She was granted 30,000 shares of common stock in the form of restricted stock units and now holds 46,660 common shares directly after this award.
She was also granted a stock option for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over several years starting March 20, 2027, contingent on continued service with the company.
Atrium Therapeutics, Inc. Chief Scientific Officer Husam Younis reported equity compensation awards. He received 30,000 shares of common stock as restricted stock units, which vest 25% on March 20, 2027 and then in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, vesting 25% on March 20, 2027 and the balance in 36 equal monthly installments through April 20, 2036. Following the stock award, his direct common stock holdings total 52,657 shares.